Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 9/20 | 0.41 |
| ▸ | F13A1 | P00488 | 7/20 | 0.41 |
| ▸ | TGM1 | P22735 | 4/20 | 0.41 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196618 | 0.87 | USP2 (0.44) | GPR119USP2SMN1; SMN2STSTGM2 | |
| SCHEMBL30183473 | 0.86 | USP2 (0.43) | GPR119USP2SMN1; SMN2STSTGM2 | |
| SCHEMBL4551353 | 0.86 | USP2 (0.43) | GPR119USP2SMN1; SMN2TGM2F13A1 | |
| SCHEMBL5214356 | 0.86 | USP2 (0.43) | GPR119USP2SMN1; SMN2STSTGM2 | |
| SCHEMBL7527689 | 0.84 | USP2 (0.42) | GPR119USP2SMN1; SMN2TGM2F13A1 | |
| SCHEMBL2253618 | 0.84 | SMN1; SMN2 (0.46) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL961058 | 0.83 | TGM2 (0.43) | GPR119USP2SMN1; SMN2TGM2F13A1 | |
| SCHEMBL2249760 | 0.83 | USP2 (0.51) | USP2SMN1; SMN2STSTGM2F13A1 | |
| SCHEMBL26113743 | 0.82 | USP2 (0.45) | GPR119USP2SMN1; SMN2STSTGM2 | |
| Hydrochloric Acid SCHEMBL12501570 | 0.81 | USP2 (0.44) | GPR119USP2SMN1; SMN2STSTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMAN-LA ROCHE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-1812445-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-12-30 | — | — | EP | disclosed |
| EP-1812446-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-11-18 | — | — | EP | disclosed |
| US-8946217-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2013-11-28 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| CN-1142161-C | Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT 4 receptor antagonists | - | 2004-03-17 | — | — | CN | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| CN-1315950-A | Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT 4 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-10-03 | — | — | CN | disclosed |
| EP-1112270-A1 | DIHYDROBENZODIOXINE CARBOXAMIDE AND KETONE DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-04 | — | — | EP | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| US-6172062-B1 | ANTISEROTONIN AGENTS; GASTROINTESTINAL DISORDERS; CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | SYNTEX (USA) LLC | 2001-01-09 | — | — | US | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000015636-A1 | DIHYDROBENZODIOXINE CARBOXAMIDE AND KETONE DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3R5 | GPR119 77/4885USP2 4236/4885SMN1; SMN2 2242/4885 |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | GPR119 239/4885USP2 2128/4885SMN1; SMN2 1500/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | GPR119 3583/4885USP2 3708/4885SMN1; SMN2 1510/4885 |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | GPR119 37/4885USP2 4409/4885SMN1; SMN2 1242/4885 |
| US-20030232808-A1 | Sulfonyl derivatives | SULT1E1, SULT2A1, SULT1A1 | GPR119 215/4885USP2 3408/4885SMN1; SMN2 1433/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | GPR119 239/4885USP2 2128/4885SMN1; SMN2 1500/4885 |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | IDO1, ZC3HAV1, AZI2 | GPR119 383/4885USP2 2294/4885SMN1; SMN2 1764/4885 |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | GPR119 37/4885USP2 4409/4885SMN1; SMN2 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.